Patents by Inventor Elizabeth Margaret Heikkila

Elizabeth Margaret Heikkila has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1
    Publication number: 20130066058
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
    Type: Application
    Filed: August 10, 2012
    Publication date: March 14, 2013
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Margaret Heikkila, Dominic Cliche, Shelley Culp-Stewart, John Gerard Flannagan, Michelle Senchyna
  • Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
    Patent number: 7381708
    Abstract: The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIF5A1.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: June 3, 2008
    Assignee: Sensco Technologies, Inc.
    Inventors: Catherine Taylor, Dominic Cliché, Elizabeth Margaret Heikkila, Diane Michelle Senchyna, John Gerard Flanagan, John E. Thompson
  • Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye
    Publication number: 20030225022
    Abstract: The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIfF5A1.
    Type: Application
    Filed: March 10, 2003
    Publication date: December 4, 2003
    Inventors: Catherine Taylor, Dominic Cliche, Elizabeth Margaret Heikkila, Diane Michelle Senchyna, John Gerard Flanagan, John E. Thompson